Microbot Medical Inc.
Microbot Medical Inc. (NASDAQ: MBOTQ) is a medical device company specializing in the research, design, and development of robotic endoluminal surgery devices for minimally invasive procedures. The company's website is www.microbotmedical.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Microbot Medical Inc. does
In the company’s own words
Microbot Medical Inc. (NASDAQ: MBOTQ) is a medical device company specializing in the research, design, and development of robotic endoluminal surgery devices for minimally invasive procedures. The company's website is www.microbotmedical.com.
The company's primary focus is the LIBERTY® Endovascular Robotic Surgical System, a fully disposable, single-use robotic platform designed to maneuver guidewires and over-the-wire devices within the body's vasculature. The LIBERTY® system received FDA 510(k) clearance in September 2025 and entered limited market release in November 2025, with full market release planned for April 2026. The system is designed to reduce radiation exposure and physical strain on physicians while eliminating the need for extensive capital equipment and dedicated catheterization laboratory rooms. The company also owns the NovaCross® product line, acquired through the purchase of substantially all assets from Nitiloop Ltd. in October 2022, which comprises intraluminal revascularization devices with integrated microcatheters.
Microbot's technology platform is co-owned with The Technion Research and Development Foundation Ltd., with the company holding an intellectual property portfolio of 29 issued or allowed patents and 52 pending patent applications worldwide, along with 14 design patents. The company has registered trademarks for LIBERTY®, NovaCross®, and related proprietary marks across multiple jurisdictions.
The company does not operate manufacturing facilities and relies on third-party manufacturers for production. Microbot established its sales, marketing, and distribution infrastructure in the United States during 2025 and has announced adoptions at Emory University Hospital and Tampa General Hospital. The company is pursuing international expansion through the CE Mark approval process, anticipated in the second half of 2026.
As of December 31, 2025, Microbot has not recognized any revenues. The company has incurred significant operating losses since inception and continues to invest heavily in research and development, with net research and development expenses of approximately $6.3 million in 2025. The company has received grants from the Israeli Innovation Authority totaling approximately $2.5 million since 2013 to support development activities.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- HINGHAM, MA
- Fiscal year end
- December
- CIK
- 883975
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Microbot Medical Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Microbot Medical Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Microbot Medical Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Microbot Medical Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Microbot Medical Inc.'s last four quarterly filings that the numbers alone won't show?”